• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Auto-injectors

Mylan must face EpiPen racketeering lawsuit

January 21, 2021 By Nancy Crotti

A federal judge in Minnesota has decided that Mylan must face a lawsuit accusing it of paying bribes and kickbacks to pharmacy benefit managers and of conspiring to fix prices on its EpiPen device. Drug wholesalers Rochester Drug CoOperative and Dakota Drug filed separate but similar lawsuits in March 2020 and June 2020, respectively, claiming […]

Filed Under: Auto-injectors, Business/Financial News, Featured, Legal News Tagged With: epipen, Mylan, Viatris

FDA approves Guerbet’s Optiray imaging bulk package

December 4, 2020 By Brian Buntz

Guerbet

Guerbet (EPA:GBT), which specializes in medical imaging including contrast agents, has received FDA approval for its Optiray imaging bulk package, which can be used to fill sterile disposable syringes for use with CT imaging.  The imaging bulk package is intended to reduce the number of single-dose vials when used with a power injector and contrast […]

Filed Under: Auto-injectors, Imaging Tagged With: Guerbet, imaging bulk package, Optiray, syringes

Xeris Pharmaceuticals launches autoinjector for severe hypoglycemia

July 1, 2020 By Danielle Kirsh

gvoke-xeris

Xeris Pharmaceuticals today said it has launched its Gvoke HypoPen glucagon injection to treat severe hypoglycemia. The autoinjector is designed to treat severe hypoglycemia in adults and children with diabetes that are ages two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% […]

Filed Under: Auto-injectors, Diabetes Tagged With: xerispharmaceuticals

Abbott, Tandem seal deal to combine CGM, insulin delivery tech

June 29, 2020 By Nancy Crotti

Abbott logo updated

Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott’s Freestyle Libre CGM with Tandem’s t:slim X2 pump to monitor glucose without fingersticks. The agreement covers the technical development of device integration […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Featured, Uncategorized, Wall Street Beat Tagged With: abbott, Tandem Diabetes Care

Tandem Diabetes Care wins expanded FDA indication for insulin pump

June 17, 2020 By Sean Whooley

Tandem Diabetes Care - updated logo

Tandem Diabetes Care (NSDQ:TNDM) announced today that it won an expanded pediatric indication from the FDA for its t:slim X2 insulin pump. The t:slim X2 with Control-IQ technology won FDA clearance for controlling Type 1 diabetes in December, which was followed by a commercial launch in the U.S. the next month. Tandem touts t:slim X2 with […]

Filed Under: Auto-injectors, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pediatrics, Regulatory/Compliance Tagged With: FDA, Tandem Diabetes Care

Abbott, Medtronic go head-to-head at ADA conference

June 15, 2020 By Nancy Crotti

Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology. The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller […]

Filed Under: Auto-injectors, Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Research & Development Tagged With: abbott, American Diabetes Association, Centers for Medicare and Medicaid Services (CMS), dariohealth, Medtronic, One Drop, Tandem Diabetes Care

Meridian Medical Technologies recalls EpiPen and EpiPen Jr auto-injectors

February 21, 2020 By Danielle Kirsh

Meridian Medical Technologies issued a voluntary recall for 13 lots of the Mylan EpiPen and EpiPen Jr. Auto-Injectors. The recall stems from the potential of the devices to contain a defective part that could result in the devices’s failure to activate. The company says the number of reported failures is small, but the defective part […]

Filed Under: Auto-injectors Tagged With: epipen, Meridian Medical Technologies, Mylan

Beta Bionics’ bionic pancreas wins breakthrough status from FDA

December 11, 2019 By Nancy Crotti

Beta Bionics - updated logo

The FDA has granted Beta Bionics breakthrough device designation for its iLet bionic pancreas system. The designation provides Beta Bionics with priority FDA review. It covers all configurations of the device  — insulin-only, glucagon-only, and bi-hormonal, including use with Zealand Pharma’s dasiglucagon, a glucagon analog in a ready-to-use aqueous solution, according to Boston-based Beta Bionics. […]

Filed Under: Auto-injectors, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Beta Bionics, FDA, Zealand Pharma

Regenxbio pulls trigger on option to license Clearside Biomedical’s SCS Microinjector

October 31, 2019 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) said yesterday that Regenxbio (NSDQ:RGNX) exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus (AAV)-based therapeutics in treating wet age-related macular degeneration, diabetic retinopathy and other conditions. The two companies inked the option and licensing deal that they said at the time could be worth more than $130 million on […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Clearside Biomedical, Regenxbio

BD launches syringe-autoinjector combo

October 21, 2019 By Nancy Crotti

Becton Dickinson (NYSE:BDX) today announced the launch of the BD Intevia 1mL two-step disposable autoinjector, which combines an autoinjector and pre-fillable syringe in one integrated system. BD Intevia disposable autoinjector is a 2-step push-on-skin device that is designed to effectively and safely inject a variety of drugs of different viscosities up to 35cP and different […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Uncategorized Tagged With: Becton Dickinson

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 10
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS